While combined PD-(L)1/CTLA-4 blockade following anti-PD-(L)1 failure has demonstrated efficacy as a salvage regimen in other cancer types, it is unknown whether this treatment sequence is effective in HCC (13, 14). Here, CTLA4 is linked to hepatocellular carcinoma.